Axsome Therapeutics, Inc. (AXSM) Stock
AXSM Key Statistics
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
CEO: Herriot Tabuteau. Company website
AXSM — Frequently Asked Questions
What is the AXSM stock price today?
Axsome Therapeutics, Inc. (AXSM) trades at $207.78, down 3.03% on the day, as of Sep 20, 2026 14:57 UTC.
What is Axsome Therapeutics, Inc.'s market cap?
Axsome Therapeutics, Inc. has a market capitalisation of $10.69B, calculated from the live AXSM share price and shares outstanding.
What is the P/E ratio of AXSM?
AXSM has no meaningful price-to-earnings ratio: Axsome Therapeutics, Inc. lost $3.75 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Axsome Therapeutics, Inc. make?
Axsome Therapeutics, Inc. generated revenue of $776.57M over the trailing twelve months, which puts the stock at 13.77 times sales.
What is the 52-week range for AXSM?
AXSM has traded between $112.90 and $260.19 over the past 52 weeks, and the last price is 20.1% below that high.
Is Axsome Therapeutics, Inc. profitable?
No. Axsome Therapeutics, Inc. is loss-making, with a net margin of -24.68% over the trailing twelve months.
What is the analyst price target for AXSM?
Wall Street analysts rate AXSM Buy, with an average price target of $282.53, 36.0% above the current price.
What sector is Axsome Therapeutics, Inc. in?
Axsome Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Axsome Therapeutics, Inc.?
Herriot Tabuteau is the chief executive of Axsome Therapeutics, Inc., which employs 1,346 people.
Where can I track AXSM in real time?
QFI Terminal shows AXSM with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See AXSM live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open AXSM in Terminal See plans